EGFR and cancer: Since a series of EGFR inhibitors such as gefitinib, erlotinib, lapatinib and vandetanib were approved for cancer therapy, and thus the 4-aminoquinazoline skeleton has been considered a promising nucleus for antitumor drug development [21].